Oncolytic Virus Engineering Services

Introduction Advantages

Oncolytic Virus Engineering

Oncolytic virus (OV) includes attenuated natural virus and genetically engineered virus. Oncolytic Virus Engineering combines genetic engineering techniques and knowledge of virology, genetic engineering, and immunology to transform OV. Creative Biolabs is committed to developing more efficient and safer tumor treatments, experienced scientists have used genetic engineering to alter the viral capsid to reduce the pathogenicity and immunogenicity of the virus, enhance the anti-tumor immune response by making the virus secrete antibodies, make OV express cytokines/chemokines to attract immune cells to migrate to the tumor site, or loading OV with immune checkpoint inhibitors.

Different ways to optimize oncolytic virotherapy. (OA Literature)Fig.1 Optimization of oncolytic virus therapy1

Pathogenicity Manipulation (Attenuation)

Creative Biolabs scientists use advanced gene editing technology to manipulate the pathogenicity of OV and achieve moderate attenuation of the virus. This will not only ensure the safe replication of OV in the human body but also effectively avoid excessive damage to normal cells, thereby improving the safety and tolerance of the treatment.

Immunogenicity Manipulation

In the process of replication and lysis of tumor cells, OV releases a large number of tumor-related antigens, activates the body's immune system, and triggers an anti-tumor immune response. Scientists at Creative Biolabs stimulate a patient's immune system by optimizing the immunogenicity of the virus so that it produces a stronger immune response to the tumor.

Antibody-expressing Oncolytic Virus

Through genetic engineering technology, the genes encoding antibodies are inserted into the genome of oncolytic viruses, and Creative Biolabs scientists develop a series of strategies to engineer OV so that it can express antigen-specific antibodies that directly target the surface of the tumor, thereby achieving precise targeting of tumor cells. This innovative therapy combines the replication ability of OV with the targeting of antibodies and provides new ideas for the treatment of tumors.

Cytokine/Chemokine-expressing Oncolytic Virus

Cytokines and chemokines can attract immune cells to the tumor site and enhance the body's anti-tumor immune response. Through genetic engineering technology, related genes are inserted into the OV genome to make it replicate in tumor cells and also express immunoregulatory cytokines or chemokines.

Immune Checkpoint Inhibitor-expressing Oncolytic Virus

Immune checkpoint inhibitors relieve the inhibitory effect of tumor cells on the immune system by blocking the activity of immune checkpoint molecules. Creative Biolabs scientists genetically engineered genes encoding immune checkpoint inhibitors into the genome of oncolytic viruses. These immune checkpoint inhibitors can act locally on tumors and enhance the anti-tumor immune response of the body.

Advantages

  • One-stop oncolytic virus engineering services, covering the whole process from viral vector screening, and gene editing to product production and quality control;
  • Experienced and creative;
  • High-quality products;
  • Customized solutions.

Reference

  1. Ji, Qing, et al. "Strategies for advanced oncolytic virotherapy: current technology innovations and clinical approaches." Pharmaceutics 14.9 (2022): 1811. Distributed under Open Access license CC BY 4.0, without modification.
! All products and services are for Research Use Only. Not For Clinical Use.
SERVICES

Online Inquiry